NFKB1 and diffuse large B-cell lymphoma: Given Dox and CTX as the conventional and first-line therapeutics to treat DLBCL, which also functioned via Notch and NF-κB signaling pathways (Supplementary Fig. 4) [26], we hypothesized that Spautin-1 might synergize with Dox or CTX.